References
- Holleman A, Monique L. Den Boer et al. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood 2003; 13: 4541–4546.
- Zhou M, Gu L, Findley H, Jiang R, Woods WG. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cane Res 2003; 63: 6357–6362.
- Vassilev LT, Vu BT, Graves B et al. In vivo activation of the p53pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844–848.
- Piette J, Neel H, Marechal V. MDM2: keeping p53 under control. Oncogenen 1997; 15: 1001–1010.
- Zhou M, Gu L, Abshire TC et al. Incidence and prognostic significance of MDM-2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 2000; 14(1): 61–67.
- Holleman A, Monique L, den Boer L et al. The expression of 70apoptosis genes in relation to lineage, genetic subtype, cellular drug. Blood 2006; 107: 769–776.
- Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao LE, Yu AL. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 1994; 84: 3105–3112.
- Mihara M, Erster S, Zaika A et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11: 577–590.
- Binder BR. A novel Application for murine double minute2 antagonists: the p53 tumor suppressor network also controls angiogenesis. Circ Res 2007; 100(1): 13–14.
- Ries S, Biederer C, Woods D et al. Opposing effects of Ras on p53:transcriptional activation of MDM2 and induction of p19ARF. Cell 2000; 103: 321–330.
- Gustafsson B, Axlsson B, Christensson B, Winiarski J. MDM-2and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors. Pediatr Hematol Oncol 2002; 18(8): 497–508.
- Konikova E, Kusenda J. Altered expression of p53 and MDM-2 proteins in hematological malignancies. Neoplasma 2003; 50: 31–40.
- Speidel D, Helmbold H, Deppert W. Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress. Oncogene 2006; 25: 940–953.
- Ganguli G, Wasylyk B. p53-Independent Functions of MDM2. Mol Cancer Res 2003; 1: 1027–1035.
- Marks DI, Kurz BW, Link MP et al. Altered expression of p53 andmdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Gun Oncol 1997; 15: 1158–1162.
- Jones SN, Hancock AR, Vogel H, Donehower LA, Bradly A. Overexpresion of MDM-2 in mice reveals a p53-independent role for MDM-2 in tumorigenesis. Proc Natl Acad Sci USA 1998; 95: 15608–15612.
- Arima Y, Nitta M, Kuninaka S et al. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem 2005; 280: 19166–19176.
- Kakudo Y, Shibata H, Otsuka K, Kato S, Ishioka C. Lack of correlation between P53 dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 2005; 65: 2108–2114.
- Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. MDM-2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-indepen-dent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006; 108(3): 993–1000.
- Harris LC. MDM-2 splice variants and their therapeutic implica-tion. Curr Cancer Drug Targets 2005; 5: 21–26.
- Kojima K, Konopleva M, Samudio IJ et al. MDM2 antago-nists induce p53 —dependent apoptosis inAML: implications for leukemia therapy. Blood 2005; 106: 3150–3159.
- Secchiero P, Corallini F, Gonelli A et al. Antiangiogenic activity of MDM-2 antagonist nultin-3. Circ Res 2007; 100: 61–69.